NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy

• Published in: Cancer Immunology, Immunotherapy : CII Immunotherapy : CII, 2024-10, Vol.73 (12), p.245, Article 245
• Main Authors: Zhang, Wanli, Shi, Xupeiyao, Huang, Shitong, Yu, Qiumin, Wu, Zijie, Xie, Wenbin, Li, Binghua, Xu, Yanchao, Gao, Zheng, Li, Guozhi, Qian, Qianqian, He, Tiandi, Zheng, Jiaxue, Zhang, Tingran, Tong, Yue, Deng, Danni, Gao, Xiangdong, Tian, Hong, Yao, Wenbing
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Antigens, Neoplasm - immunology; Cancer Research; Cancer vaccines; Cancer Vaccines - immunology; CD4 antigen; Cell culture; Epitopes; Epitopes, T-Lymphocyte - immunology; Female; Hepatocytes; Humans; Immunology; Immunosuppression; Immunotherapy; Immunotherapy - methods; Liver cancer; Liver Neoplasms - immunology; Liver Neoplasms - therapy; Lymphocytes; Lymphocytes T; Macrophages; Major histocompatibility complex; Medicine; Medicine & Public Health; Mice; Microenvironments; Neoantigens; Neoplasms - immunology; Neoplasms - therapy; Oncology; Prostaglandin E2; Tumor Microenvironment - immunology; Tumors; Vaccines; Xenograft Model Antitumor Assays
• ISSN: 1432-0851; 0340-7004; 1432-0851
• DOI: 10.1007/s00262-024-03830-2

Neoantigen vaccines represent an emerging and promising strategy in the field of tumor immunotherapy. Despite their potential, designing an effective neoantigen vaccine remains a challenge due to the current limitations in predicting CD4 + T cell epitopes with high accuracy. Here, we introduce a novel approach to neoantigen vaccine design that does not rely on computational prediction of CD4 + T cell epitopes. Utilizing nitrated helper T cell epitope containing p -nitrophenylalanine, termed “NitraTh epitope,” we have successfully engineered a series of tumor neoantigen vaccines capable of eliciting robust neoantigen-specific immune responses. With the help of NitraTh epitope, even mutations with low predicted affinity for MHC class I molecules were successfully induced to elicit neoantigen-specific responses. In H22 cell allograft and patient-derived xenograft (PDX) liver cancer mouse models, the NitraTh epitope-based neoantigen vaccines significantly suppressed tumor progression. More strikingly, through single-cell sequencing we found that the NitraTh epitope-based neoantigen vaccines regulate macrophage reprogramming and modulate macrophages to decrease the levels of the immunosuppressive molecule prostaglandin E2 (PGE2), which in turn reshapes the tumor immunosuppressive microenvironment. In summary, NitraTh epitope-based neoantigen vaccines possess the dual effects of potently activating neoantigen-specific immunity and alleviating immunosuppression, potentially providing a new paradigm for the design of tumor neoantigen vaccines.